Healthcare Services

Urinary Tract Cancer Market Size Outlook and Demand Growth Across 2026–2030

April 7, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Urinary Tract Cancer Market Between 2026 And 2030?

The urinary tract cancer market has seen rapid expansion in recent years. Its value is expected to rise from $3.84 billion in 2025 to $4.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 18.7%. This growth witnessed in the past period stems from an increase in smoking-related cancer occurrences, greater exposure to occupational carcinogens, advancements in cancer diagnostic technologies, the spread of oncology treatment centers, and improved understanding of urinary tract cancers.

The market size for urinary tract cancer is projected to undergo significant expansion in the coming years. It is expected to reach $9.29 billion by 2030, showing a compound annual growth rate (CAGR) of 19.5%. This growth throughout the forecast period is primarily driven by heightened investments in personalized oncology treatments, the increasing embrace of immunotherapy approaches, the wider availability of AI-assisted diagnostic tools, a greater emphasis on early screening programs, and advancements in minimally invasive cancer surgery. Important trends anticipated for the forecast period include a growing adoption of targeted cancer therapies, the expanding utilization of advanced diagnostic imaging techniques, a deeper integration of precision oncology methods, the broadening of multimodal treatment strategies, and an intensified focus on early cancer detection.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13059&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Urinary Tract Cancer Market?

The increasing occurrence of bladder cancer is anticipated to fuel the expansion of the urinary tract cancer market. Bladder cancer is characterized by the formation of malignant cells within the urinary bladder’s tissues, which is a hollow pelvic organ storing urine produced by the kidneys before its excretion. This heightened prevalence consequently boosts the need for diagnostic instruments, screening approaches, and therapeutic choices for individuals suffering from urinary tract cancer. As an illustration, in January 2023, a report published by the American Cancer Society Inc., a US-based voluntary organization for cancer awareness, indicated that projected cases of urinary system cancer reached 168,560 in 2023, representing a 2.66% increase from 164,190 in 2022 in the United States. Consequently, the rising incidence of bladder cancer is set to stimulate the growth of the urinary tract cancer market.

Which Market Segments Are Examined In The Urinary Tract Cancer Market Study?

The urinary tract cancer market covered in this report is segmented –

1) By Cancer Type: Bladder Cancer, Urethral Cancer, Ureteric And Renal Pelvic Cancer

2) By Treatment: Chemotherapy, Intravesical Therapy, Radiation Therapy, Surgery

3) By Diagnostic Techniques: Cystoscopy, Transurethral Resection Of The Tumor, Imaging Tests, Urine Analyses, Other Diagnostic Techniques

4) By Distribution Channel: Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Bladder Cancer: Transitional Cell Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma

2) By Urethral Cancer: Urethral Carcinoma, Urethral Tumors

3) By Ureteric And Renal Pelvic Cancer: Ureteric Cancer, Renal Pelvic Cancer

How Are Trends Shaping The Direction Of The Urinary Tract Cancer Market?

Leading companies within the urinary tract cancer market are concentrating on introducing advanced therapies, such as antibody-drug conjugate (ADC) and immune-checkpoint inhibitor combination treatments, to achieve more effective and tailored outcomes in urothelial carcinoma. These antibody-drug conjugate immune-checkpoint inhibitor combination treatments are novel therapeutic regimens designed to combine targeted cytotoxic ADCs with checkpoint inhibitors, both killing tumor cells and enhancing immune system activation, thereby improving response rates and survival in urinary tract cancers. For example, in November 2025, Astellas Pharma Inc., a Japan-based healthcare and pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for PADCEV (enfortumab vedotin-ejfv) + KEYTRUDA (pembrolizumab). This approval is for the neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer and features a Nectin-4-directed ADC component combined with PD-1 immune-checkpoint blockade. This design is specifically aimed at reducing recurrence, progression, or death by ~60% compared to surgery alone, with its regulatory path having a target action date of April 7, 2026, under the FDA’s Priority Review program.

Who Are The Primary Competitors In The Urinary Tract Cancer Market?

Major companies operating in the urinary tract cancer market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck KGaA, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC (GSK), Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Eisai Co. Ltd., Boehringer Ingelheim GmbH, Incyte Corporation, Seagen Inc., Exelixis Inc., UroGen Pharma Inc., Mersana Therapeutics, Spectrum Pharmaceuticals

Read the full urinary tract cancer market report here:

https://www.thebusinessresearchcompany.com/report/urinary-tract-cancer-global-market-report

What Are The Leading Geographic Regions In The Urinary Tract Cancer Market?

North America was the largest region in the urinary tract cancer market in 2025. The regions covered in the urinary tract cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Urinary Tract Cancer Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13059&type=smp

Browse Through More Reports Similar to the Global Urinary Tract Cancer Market 2026, By The Business Research Company

Adrenocortical Carcinoma Global Market Report

https://www.thebusinessresearchcompany.com/report/adrenocortical-carcinoma-global-market-report

Bladder Cancer Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

Urothelial Carcinoma Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795